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Background: It is known that antimalarial drugs reduce the risk of low birth weight (LBW) in pregnant patients.
However, a previous Cochrane review did not evaluate whether the level of antimalarial drug resistance could
modify the protective effect of antimalarial drugs in this regard. In addition, no systematic review exists comparing
current recommendations for malaria prevention during pregnancy to alternative regimens in Africa. Therefore, we
conducted a comprehensive systematic review and meta-analysis to assess the efficacy of antimalarial drugs for
malaria prevention during pregnancy in reducing the risk of LBW.
Methods: We searched PubMed, Embase and the Cochrane Central Register of Controlled Trials (CENTRAL) for
articles published up to 21 November 2014, in English or French, and identified additional studies from reference
lists. We included randomized and quasi-randomized studies reporting LBW as one of the outcomes. We extracted
data and assessed the risk of bias in selected studies. All pooled analyses were based on a random effect model,
and we used a funnel plot and trim and fill method to test and adjust for publication bias.
Results: A total of 25 studies met the inclusion criteria (37,981 subjects). Compared to no use, all combined
antimalarial drugs were associated with a 27 % (RR 0.73, 95 % CI 0.56–0.97, ten studies) reduction in the risk of
LBW. The level of antimalarial drug resistance modified the protective effect of the antimalarial drug used for
prevention of LBW during pregnancy. Sulfadoxine-pyrimethamine was not associated with a reduction in the
risk of LBW in regions where the prevalence of the dihydropteroate synthase 540E mutation exceeds 50 %
(RR 0.99, 95 % CI 0.80–1.22, three studies). The risk of LBW was similar when sulfadoxine-pyrimethamine was
compared to mefloquine (RR 1.05, 95 % CI 0.86–1.29, two studies).
Conclusion: Prophylactic antimalarial drugs and specifically sulfadoxine-pyrimethamine may no longer protect
against the risk of LBW in areas of high-level resistance. In Africa, there are currently no suitable alternative drugs to
replace sulfadoxine-pyrimethamine for malaria prevention during pregnancy.* Correspondence: anick.berard@umontreal.ca
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Low birth weight (LBW) is defined as a birth weight of a
live born infant of less than 2,500 g (5.5 lb) regardless of
gestational age [1]. LBW is one of the leading causes of
neonatal and infant mortality in the world and may be
the result of a short gestational period, intrauterine growth
restriction (IUGR), or a combination of both events [1].
Infants born with this adverse outcome are at higher risk
of early growth retardation, infectious diseases, develop-
mental delay, death during infancy and chronic disease
in adulthood [2, 3]. It is estimated that over 4 million
children are born each year with LBW in Africa, where
malaria infection accounts for up to 560,000 (14 %)
LBW infants and 11 % of LBW-related infant mortality [4].
Malaria is a mosquito-borne infectious disease transmitted
by a parasitic protozoan in the Plasmodium genus. This
disease leads to maternal anemia and placental parasitemia,
which are both known risk factors for LBW. This may ex-
plain the high LBW prevalence observed in regions where
malaria is endemic, and hence making the disease a poten-
tially modifiable necessary cause of LBW. Therefore, the
use of antimalarial drugs appears to be one of the most ap-
propriate interventions to prevent the deleterious effect of
malaria during pregnancy and to reduce child mortality as
recommended by the Millennium Development Goals
(MDGs) [5]. A recent Cochrane review published in
2014 reported that compared to placebo, prophylactic
antimalarial drug use during pregnancy reduced the risk
of LBW by 27 % among women in their first or second
pregnancy [6]. Previously, another meta-analysis showed
that the use of three or more doses of sulfadoxine-
pyrimethamine compared to two doses was associated
with a reduction of the risk of LBW by 23 % among
HIV-negative women [7].
World Health Organization (WHO) guidelines for the
treatment of malaria recommend that first-line treat-
ment should be changed if the total failure rate exceeds
10 % [8]. Current evidence suggests that the efficacy of
antimalarial drugs in preventing LBW may decrease with
Plasmodium resistance [9], but the threshold at which
these drugs will fail to reduce the risk of LBW remains
unclear. An earlier meta-analysis published in 2007 showed
that the level of drug resistance had no effect on the efficacy
of intermittent preventive treatment (IPT) during preg-
nancy with sulfadoxine-pyrimethamine in reducing the
risk of LBW. However, the range of resistance (19–26 %)
identified in those studies was narrow, which limited the
generalizability of this finding [10]. In contrast, a cohort
study conducted in central Africa in 2012 showed that the
level of drug resistance may modify the effectiveness of
sulfadoxine-pyrimethamine. However, this result should
be interpreted with caution given the study design limita-
tions [11]. In addition, it is currently known that high
prevalence of quintuple mutation (dihydropteroate synthase540 E mutation, dhps 540E) and sextuple mutation
(additional dhps 581G or dihydrofolate reductase, dhfr
164 L mutation to quintuple mutation) in Plasmodium
falciparum infections may interfere with sulfadoxine-
pyrimethamine effectiveness [12–15]. The 2014 Cochrane
review did not evaluate drug resistance as a modifier of
the protective effect of antimalarial drugs in reducing
the risk of LBW. In addition, there is a lack of head-to-
head randomized controlled trials (RCTs) that evaluate
potential alternatives to IPT during pregnancy with
sulfadoxine-pyrimethamine. However, given the increasing
resistance to this drug, some head-to-head RCTs compar-
ing sulfadoxine-pyrimethamine to mefloquine or antibiotics
have been published recently [16–18], but no updated
synthesis including these new trials are available in the
literature.
Therefore, the objectives of our systematic review were:
1) to quantify the protective effect of antimalarial drugs
used for the prevention of malaria during pregnancy in re-
ducing the risk of LBW compared to no use of antimalarial
drugs; 2) to examine whether the level of drug resistance
and gravidity could modify the protective effect of antimal-
arial drugs in reducing the risk of LBW; 3) to evaluate the
risk of LBW associated with the use of three doses or more
of the main types of antimalarial drugs compared to
the use of two doses of these drugs; and 4) to compare
the risk of LBW between women taking sulfadoxine-
pyrimethamine and those taking different antimalarial
drug alternatives for malaria prevention during pregnancy.
Methods
Data sources and search strategy
We followed the Preferred Reporting Items for Systematic
Reviews and Meta-Analysis (PRISMA) [19]. For a complete
PRISMA checklist, see Additional file 1. We systematically
searched PubMed, Embase and the Cochrane Central
Register of Controlled Trials (CENTRAL) for all relevant
articles, reporting associations between LBW and gesta-
tional exposure to antimalarial drugs used for the preven-
tion of malaria during pregnancy up to 21 November 2014,
with the following key words: ‘malaria’; and ‘low birth
weight’. Details of the search strategy for PubMed are
available and described in Additional file 2. The search
strategies for other databases are available upon request.
The reference lists of retrieved articles were reviewed in
order to identify studies that were not obtained from the
preliminary literature.
Study selection
Eligibility criteria for study selection included: 1) RCTs
and quasi-randomized controlled trials containing data
of pregnant women exposed to any type of antimalarial
drug used for malaria prevention, as well as a control
group (no use of antimalarial drug, placebo, or other
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come of interest (LBW). RCTs were defined as clinical
trials in which individuals or other units were assigned
to different treatment groups using randomization al-
location, such as random number, computer-generated
random sequences, coin tossing and drawing lots.
Quasi-randomized studies are clinical trials in which
individuals or other units are assigned to different
treatment groups using non-strictly random methods
of allocation. Examples of quasi-random methods of
assignment include alternation, date of birth and medical
record number [20]; 2) studies published in French or
English; and 3) studies that reported a P. falciparum infec-
tion. We excluded observational studies (cohort, case con-
trol and cross-sectional studies), case reports, case series
and unpublished data (grey literature). Studies conducted
among HIV-infected women were also discarded. Indeed,
a recent meta-analysis that included HIV-positive preg-
nant women was available in the literature [7] and since
then only one head-to-head RCT conducted among HIV-
positive pregnant women has been published [21].1306 records identified through 
database searching 
- Embase (n =716) 
- PubMed (n = 533) 
- Cochrane Register for clinical 


































Fig. 1 PRISMA flow chart for systematic review of antimalarial drugs for ma
weight (LBW)After the initial search strategy, two independent re-
viewers (FTM and AB) used the inclusion and exclusion
criteria to screen titles of abstracts and assessed only full
texts of relevant studies for eligibility. Disagreements were
resolved by consensus. All studies that did not meet inclu-
sion criteria were excluded with reasons provided in a flow
chart (Fig. 1).
Data extraction
Two investigators (FTM and AB) extracted the following
information in a standardized form: first author’s name;
publication year; period of study; location; study design;
number of women enrolled; risk of LBW in exposed and
control group; dropout rates in each trial; local malaria
transmission rates; and level of antimalarial drug resist-
ance (clinical and molecular resistance).
Clinical resistance to antimalarial drugs was defined by
treatment failure rates at day 14 or 28 in symptomatic
children aged 6–59 months in the study region [22]. If
available, data on transmission level and therapeutic fail-
ure to antimalarial drugs in children aged 6–59 months5 additional records identified 
through other sources 
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cluded in our review.
We used this subpopulation to evaluate efficacy of
antimalarial drugs, given that most RCTs included in
our review were carried out when assessment of efficacy
of these drugs involved children under 5 years old of age.
Moreover, a previous meta-analysis also used a therapeutic
failure rate of children under 5 years old to assess the
effect of sulfadoxine-pyrimethamine resistance on the
efficacy of intermittent preventive therapy for malaria
control during pregnancy [10].
Molecular resistance to sulfadoxine-pyrimethamine was
defined by the prevalence of molecular markers of P.
falciparum resistance to sulfadoxine-pyrimethamine (dhps
540E) in symptomatic children aged 6–59 months. We
used data obtained from a database that mapped dhfr
and dhps gene distribution associated with sulfadoxine-
pyrimethamine resistance in Africa [9, 12, 23]. This map is
currently used as a tool to track the spatial extent and
temporal patterns of sulfadoxine-pyrimethamine resist-
ance mutations across the African continent [12].
This method is the gold standard for monitoring antimal-
arial drug efficacy and helps policy makers shape recom-
mendations for malaria treatment and prophylaxis [24].
Risk ratios (RRs; intention-to-treat and per-protocol
estimates) along with 95 % confidence intervals (CIs) were
extracted from all included studies. When the measure of
association was not reported, we calculated unadjusted
risk ratios by means of the Mantel–Haenszel chi-squared
test. Therefore, we used the risk ratio as the main effect
measure in this review.
Risk of bias in individual studies
The risk of bias for each study included in the review
was assessed independently by two authors using the
Cochrane Collaboration’s tool for assessing risk of bias
of RCTs [25]. Disagreement was resolved through con-
sensus after discussion in integrative session. The tool
covers six bias domains: 1) sequence generation describes
the method used to generate the allocation sequence in suf-
ficient detail to allow an assessment of whether it should
produce comparable groups; 2) allocation concealment de-
scribes the method used to conceal the allocation sequence
in sufficient detail to determine whether intervention
allocations could have been foreseen before or during
enrolment; 3) blinding of participants and personnel
describes all measures used, if any, to blind trial participants
and researchers from knowledge of which intervention a
participant received; 4) incomplete outcome data describes
the completeness of outcome data for each main outcome
including attrition and exclusions from the analysis; 5) se-
lective reporting describes how selective outcome reporting
was examined and what was found; and 6) other source
of bias describes any important concerns about bias notcovered in the other domains in the tool [25]. Based on
empirical and theoretical considerations [25], RCTs with
inadequate random sequence generation, allocation con-
cealment, attrition [26] or reporting bias were considered
as studies with a high risk of bias. When sufficient infor-
mation was not provided on these different domains of
bias to allow a definite judgement, we considered that the
risk of bias was unclear. In contrast, when a study was free
of these biases, we considered the risk of bias as low.Statistical analysis
We calculated the summary risk ratios and 95 % confi-
dence intervals using a random effect model (method of
DerSimonian and Laird) due to differences between study
populations and interventions [27]. This model considers
the variation within and between RCTs in their calculation
of the overall effect size [20]. Given that the RCTs in-
cluded in our review were carried out across different
countries in Africa, with different populations, interven-
tions and levels of antimalarial drug resistance [9, 12, 23],
we assumed that the random effect model was the most
appropriate model to calculate the summary estimate for
all analyses.
In the sensitivity analysis, we used a fixed effect model
to test the robustness of our findings [20]. Pooled esti-
mates of each meta-analysis and estimates of individual
studies also with their 95 % CI were presented in a forest
plot. Heterogeneity was explored graphically and quanti-
fied with the I2 statistic, which provides the percentage
of the variability in effect estimates that is due to hetero-
geneity rather than sampling error (chance) [28]. When
the value of the I2 statistic was found to be higher than
50 %, representing significant heterogeneity [20], we
identified outliers using a Galbraith plot. We attempted
to explain this heterogeneity by stratification according
to the level of clinical resistance to antimalarial drugs
(treatment failure rates in symptomatic children at day
14 or 28), gravidity and risk of bias of studies included.
To investigate the association between clinical resist-
ance and the efficacy of antimalarial drugs in reducing
the risk of LBW, we used a 10 % threshold for treatment
failure rate, which is the current cut-off recommended
by the WHO for policy change in malaria areas [8]. We
also restricted our analysis of trials conducted in East
Africa, where the prevalence of the dihydropteroate syn-
thase 540E mutation (a proxy of high-level sulfadoxine-
pyrimethamine resistance) exceeds 50 %, to examine the
association between molecular resistance to sulfadoxine-
pyrimethamine and its efficacy in reducing LBW [23].
This threshold for molecular markers has also been
used, as recommended by the WHO, stating that inter-
mittent preventive treatment of infants (IPTi) with
sulfadoxine-pyrimethamine should not be implemented
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infected individuals exceeds 50 % [23].
We evaluated publication bias by visual inspection of a
funnel plot (eyeball test) and by Egger’s [29] and Begg’s
test [30], and adjusted for possible publication bias by
means of the trim and fill method [31]. We performed a
sensitivity analysis with a fixed effect model (inverse
variance method) and conducted additional analysis by
removing outliers identified by a Galbraith plot.
We also investigated the influence of each individual
study on the overall meta-analysis summary estimate after
removal of each trial one at a time from the meta-analysis.
We quantified the difference between risk estimate of trials
with low risk of bias compared to trials with high risk and
unclear risk of bias using random effect meta-regression in
our main meta-analysis. Pooled analysis was based on
intention-to-treat estimates when provided in the trial.
Otherwise, per-protocol estimates were used. All analyses
were performed using Stata version 12.1 (StataCorp LP,
College Station, TX, USA).Results
Study selection
A total of 1,306 articles were initially identified. After re-
moving duplicates, 818 articles remained for further
consideration. Screening article titles and abstracts led
to the exclusion of an additional 730 articles, and the as-
sessment of 88 full-text articles for possible inclusion.
After reviewing the reference list of eligible articles, five
additional articles were added for possible inclusion. Of
those 93 articles, 25 met the inclusion criteria [16–18,
32–53] and 68 were excluded. The list of the reasons for
the exclusions is provided (Fig. 1). The flow of studies
through the screening process of the review is shown in
Fig. 1 and reported based on PRISMA guidelines.Study characteristics
Data from 37,981 pregnant women across the included
studies (range: 266 to 5,775) were analyzed in our re-
view. Ten studies compared any type of antimalarial
drug (chloroquine, sulfadoxine-pyrimethamine, meflo-
quine, dapsone-pyrimethamine) to a placebo or no use
of antimalarial drug; five studies compared three doses or
more versus two doses of sulfadoxine-pyrimethamine; two
studies compared weekly doses versus two doses of
chloroquine; five studies compared IPT with sulfadoxine-
pyrimethamine versus weekly chloroquine; two studies
compared IPT with sulfadoxine-pyrimethamine versus
IPT with mefloquine; and the remaining studies compared
IPT with amodiaquine-sulfadoxine-pyrimethamine com-
pared to IPT with sulfadoxine-pyrimethamine alone (one
study), and IPT with sulfadoxine-pyrimethamine versus
daily cotrimoxazole (one study).The median dropout rate of studies included in the re-
view was 14.1 % (interquartile range (IQR): 8.55–21.45 %;
range: 1.5–51 %). The rate of loss to follow-up did not sig-
nificantly differ between the exposed and control group
when reasons were provided in the study. Four trials
showed a significant difference in the rate of adverse
events between the exposed and control group [16, 39, 40,
46]. The first trial conducted by Clerk and colleagues
showed that women taking amodiaquine-sulfadoxine-
pyrimethamine were more likely to report an adverse
event than those taking sulfadoxine-pyrimethamine alone
(RR 1.88, 95 % CI 1.70–2.07), but no women were with-
drawn from the study because of an adverse event [39].
The second trial carried out in Thailand by Nosten and
colleagues reported a significant difference of the rate of
stillbirth between women who were taking mefloquine
compared to women exposed to a placebo (P <0.01) in the
first phase of the study, but as this increase was unex-
pected the author conducted a second phase in the trial
and pooled the data from the two periods that showed no
significant difference in the rate of stillbirth between
women exposed to mefloquine and control (P = 0.13) [46].
The third trial, which was a multicentre study, showed
that the number of women with serious adverse events
was higher in the mefloquine group compared to the
sulfadoxine-pyrimethamine group, but a causal rela-
tionship could not be established by members from
the data and safety monitoring board (DSMB) of the
trial [16]. The fourth trial conducted by Briand and
colleagues in Benin showed that adverse events were
more commonly associated with the use of mefloquine
compared to sulfadoxine-pyrimethamine (prevalence: 78 %
versus 32 %; P <0.01) [40].
No significant differences in the rate of adverse events
or foetal loss were found in the remaining studies [17,
18, 32–38, 41–45, 47–53]. Ten trials (40 %) reported
using intention-to-treat analysis [17, 18, 32, 33, 41, 43,
44, 47, 49, 53]; two trials (8 %) carried out a modified
intention-to-treat analysis [16, 40]; and the remaining 13
studies (52 %) used a per-protocol analysis [34–39, 42,
45, 46, 48, 50–52]. A summary of included studies evalu-
ating the use of antimalarial drugs for preventing malaria
during pregnancy and the risk of LBW is shown in
Additional file 3: Table S1.Risk of bias in individual studies
Of the 25 studies included, only four studies (16 %) were
considered as having a low risk of bias [16, 37, 49, 53]
and 17 studies (68 %) were judged as presenting a high
risk of bias [17, 18, 32–36, 38, 43–48, 50–52]. The risk
of bias was unclear in the remaining four studies (16 %)
[39–42]. A table including the risk of bias of studies is
available and described in Additional file 4: Table S2.
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Antimalarial drugs for prevention of malaria during
pregnancy compared to no use of antimalarial drug and
risk of LBW: meta-analysis
When all combined antimalarial drugs used for prevention
of malaria during pregnancy were compared to no use of
antimalarial drug, we detected a significant 27 % reduction
in the risk of LBW (RR 0.73, 95 % CI 0.56–0.97; I2 = 70 %,
P <0.01, ten studies) (Fig. 2). As heterogeneity was high
(hinging I2 statistic = 70 %), we identified an outlier across
the ten trials using a Galbraith plot (Additional file 4:
Figure S1). The excluded outlying study used a cluster
randomized design in which the units of analysis (health
centres) were not selected randomly; this may introduce a
selection bias. In addition, statistical analysis did not take
into account efficiently variability within and between
clusters. This may explain why this study was an outlier in
our analysis.
After removal of this outlier, heterogeneity between
studies decreased from 70 % to 44.1 % (RR 0.86, 95 % CINOTE: Weights are from random effects analysis
Overall  (I-squared = 70.0%, p = 0.000)
Menendez et al, (54) 2008  (Mozambique)
Mbaye et al, (33) 2006  (Gambia)
Challis et al, (42) 2004  (Mozambique)
Nosten et al, (47) 1994  (Thailand)
Gies et al, (36) 2009  (Burkina-Faso)
Ndyomugyenyi et al, (43) 2000 (Uganda)
Cot et al, (39) 1992  (Burkina faso)
Greenwood et al, (53) 1989  (Gambia)
ID
Ndyomugyenyi et al, (50) 2011  (Uganda)
Cot et al, (49) 1995 (Cameroon)
Study
.2 .5
Favors antimalarials                                                          
Fig. 2 Antimalarial drugs compared to no use of antimalarial drugs and ris
representing the relative risk together with its confidence interval. The area
meta-analysis. The combined relative risk and its confidence interval are rep
test for heterogeneity. DerSimonian and Laird were used to calculate the r
RR, relative risk0.70–1.05; I2 = 44.1 %, P = 0.074, nine studies) (Additional
file 5: Figure S2). There was a suggestion of a publication
bias (Egger’s test, P = 0.033; Begg’s test, P = 0.032)
(Additional file 5: Figure S3), but the trim and fill
method indicated no missing studies with a crude esti-
mate similar to the adjusted estimate (Additional file
5: Figure S4 and Table S3). In a sensitivity analysis, we
performed a meta-analysis using a fixed effect model,
which also showed a significant reduction in the risk
of LBW when comparing all the combined antimalarial
drugs for prevention of malaria during pregnancy to no
use of these drugs (Additional file 5: Figure S5). There
was no influence of each individual study on the overall
meta-analysis summary estimate after removal of each
trial one at a time from the meta-analysis (Additional
file 5: Table S4). When we stratified according to the
risk of bias, the treatment effect estimate was different
in each subgroup of risk of bias with overlapping confi-
dence intervals (test for heterogeneity between subgroups:


























                                    Favors no use of antimalarials
k of LBW. Each study is displayed as a square and horizontal line,
of the square represents the weight that the study contributes to the
resented by the diamond. The P value after I2 represents chi-square
andom effect model. CI, confidence interval; LBW, low birth weight;
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after using a meta-regression analysis (P >0.05) (Additional
file 5: Table S5).
Association between level of drug resistance and
gravidity and the efficacy of antimalarial drugs in
reducing LBW: meta-analysis
When all the combined antimalarial drugs used for pre-
vention of malaria during pregnancy were compared to
no use of antimalarial drug according to the level of drug
resistance based on therapeutic failures at day 14 or 28,
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Subtotal  (I-squared = 72.4%, p = 0.001)
Gravidity: G3 and more
Mbaye et al, (33)  2006
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Fig. 3 All the combined antimalarial drugs compared to no use of antimal
gravidity. Each study is displayed as a square and horizontal line representi
the square represents the weight that the study contributes to the meta-
represented by the diamond. The P value after I2 represents chi-square te
the random effect model. G1–G2 indicates first and second pregnancy; G
subgroup difference between each level of drug resistance (P <0.01). Test for
CI, confidence interval; LBW, low birth weight; RR, relative risktrials conducted in regions where the level of antimalarial
drug resistance was less than 10 % (RR 0.29, 95 % CI 0.18–
0.48; I2 = 0.0 %, P = 0.479, two studies), but not in trials
conducted in regions where the level of antimalarial drug
resistance was over 10 % (RR 0.92, 95 % CI 0.65–1.31;
I2 = 42.3 %, P = 0.177, three studies) (test for heterogeneity
between subgroups: P <0.01) (Fig. 3). When sulfadoxine-
pyrimethamine was compared to no antimalarial drug
use in trials conducted in East Africa, where the level
of sulfadoxine-pyrimethamine resistance based on the
prevalence of 540E mutation exceeds 50 %, we found
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arial drugs and risk of LBW stratified by level of drug resistance and
ng the relative risk together with its confidence interval. The area of
analysis. The combined relative risk and its confidence interval are
st for heterogeneity. DerSimonian and Laird were used to calculate
3 and more indicates two or more previous pregnancies. Test for
subgroup difference between each stratum of gravidity (P = 0.102).
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(Additional file 5: Figure S7). After stratifying by gra-
vidity, we also noted a significant reduction in the risk
of LBW in primigravidae and secundigravidae (RR 0.59,
95 % CI 0.39–0.90; I2 = 72.4 %, P = 0.01, seven studies),
but there was no reduction among higher-order multi-
gravidae (RR 0.92, 95 % CI 0.71–1.20; I2 = 16.5 %, P =
0.274, three studies); however, confidence intervals
overlapped (test for heterogeneity between subgroups:
P = 0.102) (Fig. 3).
Three doses or more of the main types of antimalarial
drugs compared to two doses of these drugs and risk of
LBW: meta-analysis
When three doses or more of sulfadoxine-pyrimethamine
were compared to two doses of this drug, we found a sig-
nificant 25 % reduction in the risk of LBW (RR 0.75, 95 %
CI 0.59–0.96; I2 = 27.1 %, P = 0.241, five studies) (Fig. 4).
No evidence of publication bias was detected afterNOTE: Weights are from random effects analysis
.
.
Three or more vs  two doses of sulfadoxine -pyrimethamine
Parise  et al, (46) 1998 (Kenya)
Filler et al, (44)2006  (Malawi)
Valea et al, (45) 2010 (Burkina-Faso)
Luntamo et al, (18) 2010  (Malawi)
Diakite et al, (38) 2011 (Mali)
Subtotal  (I-squared = 27.1%, p = 0.241)
Weekly chloroquine chemoprophylaxis  vs two doses of chloroquine
Kayentao et al, (34) 2005* (Mali)
Tiono et al,(48) 2009* (Burkina-Faso)
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Fig. 4 Three doses or more compared to two doses of the main type of an
risk of LBW. Each study is displayed as a square and horizontal line represe
the square represents the weight that the study contributes to the meta-anal
by the diamond. The P value after I2 represents chi-square test for heterogene
model. *Relative risk has been calculated with the Mantel–Haenszel method i
interval; LBW, low birth weight; RR, relative riskinspection of the funnel plot (Egger’s test, P = 0.901;
Begg’s test, P = 1.000) (Additional file 5: Figure S8). In a
sensitivity analysis, a significant reduction of LBW was also
found when using a fixed effect model (RR 0.77, 95 % CI
0.63–0.93; I2 = 27.1 %, P = 0.241, five studies) (Additional
file 5: Figure S9). There was no influence of each individual
study on the overall meta-analysis summary estimate after
removal of each trial one at a time from the meta-analysis
(Additional file 5: Table S6).
When weekly chloroquine chemoprophylaxis was com-
pared to two doses of chloroquine, no significant reduction
in the risk of LBW was found (RR 1.13, 95 % CI 0.70–1.83,
two studies) (Fig. 4).
Sulfadoxine-pyrimethamine compared to antimalarial
drug alternatives for malaria prevention during
pregnancy and risk of LBW: meta-analysis
Compared to chloroquine, sulfadoxine-pyrimethamine was






















                                      Favors two doses
timalarial drug used for prevention of malaria during pregnancy and
nting the relative risk together with its confidence interval. The area of
ysis. The combined relative risk and its confidence interval are represented
ity. DerSimonian and Laird were used to calculate the random effect
nstead of using the odds ratio (OR) provided in the paper. CI, confidence
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six studies) (Fig. 5). After visual inspection of the funnel
plot, there was no evidence of publication bias using Egger’s
test (P = 0.389) and Begg’s test (P = 0.327) (Additional file
5: Figure S10). In addition, we conducted a sensitivity ana-
lysis using a fixed effect model, which showed a reduction
of LBW when sulfadoxine-pyrimethamine was compared
to chloroquine (RR 0.61, 95 % CI 0.48–0.77) (Additional file
5: Figure S11). When sulfadoxine-pyrimethamine was com-
pared to mefloquine, the risk of LBW was similar between
the two groups (RR 1.05, 95 % CI 0.86–1.29; I2 = 32.2 %,
P = 0.225, two studies) (Fig. 5).
There was no association with a reduction in the risk
of LBW when sulfadoxine-pyrimethamine was compared
to sulfamethoxazole-trimethoprim (RR 0.62, 95 % CI
0.25–1.52, one study) (Fig. 5).
When the combination azithromycin-sulfadoxine-
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Fig. 5 Sulfadoxine-pyrimethamine compared to different antimalarial drug
LBW. Each study is displayed as a square and horizontal line representing t
square represents the weight that the study contributes to the meta-analysis.
the diamond. The P value after I2 represents chi-square test for heterogeneity.
*Relative risk has been calculated with the Mantel–Haenszel method instead o
LBW, low birth weight; RR, relative riskalone, we detected a significant reduction in the risk of
LBW (RR 0.64, 95 % CI 0.43–0.97, one study) (Fig. 5).Discussion
This systematic review and meta-analysis showed that
antimalarial drugs used for malaria prevention during
pregnancy was associated with a 27 % reduction in the
risk of LBW when compared to no use of these drugs.
These findings corroborate a previous Cochrane review,
which found an association between the use of these drugs
and the reduction of the risk of LBW in women in their
first and second pregnancy (RR 0.73, 95 % CI 0.61–0.87,
eight studies) [6]. Our reviews showed that antimalarial
drugs were effective at reducing the risk of LBW in re-
gions where the level of drug resistance was less than
10 %, but not in regions with a level of drug resistance
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alternatives for malaria prevention during pregnancy and the risk of
he relative risk together with its confidence interval. The area of the
The combined relative risk and its confidence interval are represented by
DerSimonian and Laird were used to calculate the random effect model.
f using the odds ratio (OR) provided in the paper. CI, confidence interval;
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each subgroup.
Similar findings were reported recently in a study show-
ing that the effectiveness of sulfadoxine-pyrimethamine in
preventing LBW varied with level of resistance to this
medication [11]. In contrast, an earlier meta-analysis
published in 2007 showed that evaluating sulfadoxine-
pyrimethamine resistance on the efficacy of intermittent
preventive therapy for malaria control during pregnancy
found no association with the level of drug resistance [10].
However, this finding was based on a small number of
studies conducted in a region with a narrow range of
resistance to sulfadoxine-pyrimethamine (19–26 %), which
may explain the lack of association. In addition, we demon-
strated that sulfadoxine-pyrimethamine was not associated
with a reduction in the risk of LBW in East Africa, where
the prevalence of dihydropteroate synthase 540E mutation
exceeds 50 %. Moreover, the sextuple mutant parasite has
also been recently reported in this region [12]. Indeed,
it is known that these mutations may interfere with
sulfadoxine-pyrimethamine effectiveness [12–15].
Three RCTs were included in our meta-analysis of
East Africa [41, 49, 53]. The first one was conducted in
Kabale in Uganda [49], a region where sextuple mutant
haplotype (dhps 540E mutation with additional dhps
581G) were prevalent [12]. But, the second and third
RCTs were performed in Mozambique where this muta-
tion has not been reported yet [41, 53]. Nonetheless, as
it might take an average of 5 years between the collection
of information on molecular markers and the date of pub-
lication of the results [12], the mutation might be present
in Mozambique but not yet detected.
In contrast, another meta-analysis comparing the risk
of LBW between women taking three or more doses of
sulfadoxine/pyrimethamine to those taking two doses re-
ported a similar risk of LBW in regions with prevalence
of dihydropteroate synthase 540E mutation of less or
over 50 % [7]. A possible explanation was that an extra
dose of sulfadoxine-pyrimethamine compensates for any
reduction in efficacy of the two-dose regimen resulting
from a progressive decrease of the duration of post-
treatment prophylaxis. Nevertheless, this finding should
be interpreted with caution. Indeed, it was based on a
subgroup analysis with only two studies conducted in
regions where the prevalence of dhps 540E mutation
was over 50 % and five studies conducted in regions
where the prevalence of dhps 540E mutation was less
than 50 %. Therefore, a lack of statistical power could
not be completely ruled out. However, the lack of asso-
ciation found in that study may also be explained by
the fact that the two RCTs were conducted in regions
where sextuple mutant parasites were absent.
Of note, East Africa is also a region where the prevalence
of HIV infection is high; therefore, our findings highlightthe need to address the association between HIV and
malaria co-infection and the occurrence of adverse
pregnancy outcomes, such as LBW. Our study failed
to demonstrate an interaction between gravidity and
the effect of antimalarial drugs on the risk of LBW;
however, this finding should be interpreted with caution
given the low statistical power.
Compared to two doses of sulfadoxine-pyrimethamine,
three doses or more was significantly associated with a
25 % reduction in the risk of LBW in this review. This
result was similar to a recent meta-analysis, which
showed a lower risk of LBW when three doses or more
of sulfadoxine-pyrimethamine were compared to two
doses [7].
When sulfadoxine-pyrimethamine was compared to
mefloquine, the most promising alternative for malaria
prevention during pregnancy, the risk of LBW was similar
between the two groups. In contrast, when combination
azithromycin-sulfadoxine-pyrimethamine was compared
to sulfadoxine-pyrimethamine alone, we noted a 36 % re-
duction in the risk of LBW. However, we could not draw a
definite conclusion given the limited data available in
the literature. Furthermore, additional medicines for
the prevention of malaria in pregnancy are the subject
of trials underway through the Malaria in Pregnancy
(MiP) Consortium.
To our knowledge, this is the most comprehensive and
updated synthesis of all antimalarial drugs used for the
prevention of malaria during pregnancy and the risk of
LBW. In addition, our study evaluated the association
between antimalarial drug resistance (based on treat-
ment failures of antimalarial drugs at day 14 or 28 and
on the prevalence of molecular markers of sulfadoxine-
pyrimethamine resistance in symptomatic children aged
6–59 months) and gravidity, and the protective effect of
antimalarial drugs in reducing LBW. Furthermore, we
attempted to explain heterogeneity between the studies
and performed sensitivity analyses that showed the ro-
bustness of our results.
Nevertheless, this review has some limitations. First,
measurement of antimalarial drug resistance was per-
formed on infected children with acute malaria aged 6–59
months, which may not reflect the true resistance in
asymptomatic pregnant women as they might still have
partial immunity. Given that, it is currently recommended
to use asymptomatic pregnant women instead of children
under 5 years of age to assess the efficacy of IPT during
pregnancy with sulfadoxine-pyrimethamine at different
study sites [54]. Therefore, efforts are made to test and
incorporate this new approach within national malaria
control programs across Africa [55]. However, translating
WHO recommendations into national malaria policy re-
mains challenging. A study showed a discrepancy between
current WHO recommendations during pregnancy and
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Therefore, considering that no alternative for sulfadoxine-
pyrimethamine will be available soon, the use of thera-
peutic failure to sulfadoxine-pyrimethamine in children
under 5 years old still brings additional evidence to
determine the threshold at which this drug fails to
provide any benefit during pregnancy, especially in sites
where data on molecular markers of P. falciparum resist-
ance to sulfadoxine-pyrimethamine are not yet available,
or data on efficacy of IPT with sulfadoxine-pyrimethamine
measured among asymptomatic pregnant women in
malaria sentinel sites are lacking [11].
Second, data on folic acid use, impregnated bed nets
or the pattern of transmission of malaria were not avail-
able for each study to assess whether these factors may
affect the protective effect of antimalarial drug in redu-
cing LBW.
Third, approximately two-thirds of the studies in-
cluded in this systematic review had a high risk of bias;
however, after stratification of studies according to the
risk of bias (high, unclear and low risk of bias) in the
main meta-analysis, we found no significant difference
between risk estimates of each subgroup using a meta-
regression analysis. Although there was a limited num-
ber of RCTs in each stratum of risk of bias, a recent
simulation study showed that linear regression models
require only two subjects per variable for an adequate
estimation of regression coefficients, standard errors and
confidence intervals [57]. Given that a meta-regression
concept is similar to simple linear regression [58], we are
confident that our analysis gave an unbiased regression
coefficient estimate even though it does not rule out a lack
of statistical power. In addition, two out of four (50 %)
studies with low risk of bias included in our main meta-
analysis were conducted in regions where the prevalence
of dihydropteroate synthase 540E exceeds 50 %. This may
also explain the variability of the risk estimates between
studies stratified according to the risk of bias (clinical
heterogeneity).
Fourth, the median dropout rate of studies included in
the review was 14.1 %. Furthermore, half of the studies
reported using intention-to-treat analysis, but it was in
fact an available case analysis because data were ana-
lyzed according to the assigned intervention for every
participant for whom the outcome was obtained and no
missing data were imputed. This may introduce a selec-
tion bias and limit the generalizability of this finding.
However, when the rate of loss to follow-up and the rate
of adverse events and foetal loss were provided in those
trials, there was no significant difference between the
exposed group and the control group in our main
meta-analysis.
Fifth, we did not include unpublished data in our review,
which may introduce a reporting bias in meta-analyses.Nevertheless, there was no evidence of publication bias
when using a funnel plot or trim and fill method.
Sixth, there was no control for the dose or the method
of delivery of mefloquine (IPT or weekly) in the study
conducted by Nosten and colleagues in Thailand, which
is a source of potential bias. However, when each study
was removed one at a time from the main meta-analysis,
there was no influence of each individual study on the
overall meta-analysis summary estimate.
Seventh, the safety of antimalarial drugs during preg-
nancy is a concern. Despite the fact that many RCTs have
reported antimalarial side effects, very few use appropriate
methods of pharmacosurveillance to detect and evaluate
safety signals. Therefore, there is a need to implement
standardized methods of collecting and reporting adverse
events in RCTs, which will help to build a centralized
pharmacovigilance database and efficiently identify safety
concerns.
Eighth, LBW may be a consequence of small for gesta-
tional age (SGA), preterm birth (PTB), or a combination
of both. SGAs are not systematically reported in RCTs
as an outcome of interest. In our review, only one RCT
has reported SGA as one of the outcomes [46]. However,
a recent Cochrane systematic review and meta-analysis
showed that antimalarial drugs were not associated with
PTB [6]. Another meta-analysis also showed no differ-
ence in PTB when three doses or more of sulfadoxine-
pyrimethamine were compared to two doses of this drug
[7]. Therefore, the association found with LBW may
mainly reflect an association with fetal growth rather
than with PTB. Nonetheless, further RCTs assessing
both SGA and PTB are needed.
Ninth, there is a potential for misclassification of the
outcome of LBW as the timing of measurement, method
of gestational age estimation and details on the scales
used for birth weight were not often provided in RCTs
included in our review. This may introduce a non-
differential outcome misclassification, which may bias
estimates toward a null effect. However, this limitation
regarding timing of measurement, method of gestational
estimation and scales used for birth weight is common
for RCTs conducted among pregnant women in malaria-
endemic regions [59]. This highlights the need for a
standardized method for birth weight measurement
and reporting in future studies.
Conclusions
In summary, prophylactic antimalarial drug use during
pregnancy is associated with a reduction in the risk of
LBW. There was a dose–response relationship in terms
of risk reduction of LBW when three doses or more of
sulfadoxine-pyrimethamine were compared to two doses.
However, the level of antimalarial drug resistance but not
gravidity modified the protective effect of antimalarial
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reducing the risk of LBW. Sulfadoxine-pyrimethamine
may no longer be effective at preventing the risk of LBW
in East Africa. To date, there are no suitable alternative
drugs to replace sulfadoxine-pyrimethamine for malaria
prevention during pregnancy in Africa but additional
medicines for the prevention of malaria in pregnancy
are the subject of trials underway through the MiP
Consortium.
Our study supports the current WHO recommenda-
tion for IPT with three doses or more of sulfadoxine-
pyrimethamine during pregnancy for malaria prevention.
However, there is an urgent need to re-evaluate the efficacy
of IPT during pregnancy with sulfadoxine-pyrimethamine,
especially in East Africa given the increase of resistance.
Also, additional medicines to replace this medication
are needed as no suitable alternative drug is available.
The continued monitoring of the effectiveness of IPT
during pregnancy with sulfadoxine-pyrimethamine in
Africa is essential.
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